PanCAN Manager of Research, Education and Communication Nicolas Clifford talks about the newest developments related to cancer cachexia and ways to take action.
Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients with ...
Analyses of RNA expression reveal molecules underpinning the cancer-associated process of skeletal-muscle wasting, a ...
Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...
London, UK – 7 September 2023. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and ...
Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback